Lanean...
Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors
PURPOSE: Sorafenib and everolimus are both active against neuroendocrine tumors (NET). Because of potential synergy between VEGF pathway and mTOR inhibitors, we performed a phase I study to evaluate the safety and feasibility of combining sorafenib and everolimus in patients with advanced NET. METHO...
Gorde:
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2013
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4029418/ https://ncbi.nlm.nih.gov/pubmed/23475104 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2118-9 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|